Biocon launched Gilead Sciences’ Hepatitis C drug – CIMIVIR-L in India

Recent Articles

• What are the difference between Wholesaler and Specialty Pharmacy?
• What is Scale-Up and Post Approval Changes (SUPAC) report?
• What is the meaning of scale up in pharmaceutical industry?
• RIL arm acquires stake in Strand Life Sciences for Rs. 393 crore
• DRL enters agreement to sell its rights to anti-cancer agent E7777 to Citius Pharma
• Takeda and Frazier announced a collaboration to launch HilleVax, Inc, a biopharmaceutical company, to develop and commercialize Takeda’s norovirus vaccine candidate
• Nucala received USFDA approval to treat chronic rhinosinusitis with nasal polyps
• Case Insight: Piramal Pharma’s acquisition of Hemmo Pharmaceuticals
• FDC launches Favipiravir oral suspension to treat mild to moderate cases of COVID-19
• Rossari Biotech to acquire Tristar Intermediates
• Sun Pharma launches a special initiative ‘Sunkalp’ for the welfare of doctors
• Case Insight – ANI Pharmaceuticals acquisition of Novitium Pharma
• Astrazeneca has been given the all-clear to buy rare disease drug maker Alexion in a blockbuster £28billion deal.
• Kintor Pharmaceutical collaborates with Fosun Pharma Development to Commercialise Proxalutamide
• Codexis’s CodeEvolver platform technology transfer deal with Novartis
• Lupin’s Somerset plant received US FDA warning letter for
• What is Cytokine Storm?
• FDA Grants Accelerated Approval for Alzheimer’s drug Aduhelm
• Insight on Neurogastrx licensing deal with Daewoong Pharmaceutical to Develop Fexuprazan
• Case study – Adagrasib out licensing deal